

Last Name:	Firs	rst Name: Middle Initial:
DOB:	Street A	Address:
Medical School:		City:
Cell Phone:		State:
Primary Email:	Z	ZIP Code:
Student ID:		

MMR (Measles, Mumps, Rubella) – 2 doses of MMR vaccine or two (2) doses of Measles, two (2) doses of Mumps and (1) dose of Rubella; or serologic proof of immunity for Measles, Mumps and/or Rubella. Choose only one option.						
Option 1	Vaccine Date					
MMR -2 doses of MMR	MMR Dose #1					
vaccine	MMR Dose #2					
Option 2	Vaccine or Test	Date				
Measles	Measles Vaccine Dose #1		Se	erology Results		
-2 doses of vaccine or positive serology	Measles Vaccine Dose #2		Qualitative Titer Results:	☐ Positive ☐ Negative		
positive serology	Serologic Immunity (IgG antibody titer)		Quantitative Titer Results:	IU/ml		
	Mumps Vaccine Dose #1		Serology Results			
Mumps -2 doses of vaccine or positive serology	Mumps Vaccine Dose #2		Qualitative Titer Results:	☐ Positive ☐ Negative		
positive serology	Serologic Immunity (IgG antibody titer)		Quantitative Titer Results:	IU/ml		
			Serology Results			
Rubella -1 dose of vaccine or	Rubella Vaccine	/	Qualitative Titer Results:	☐ Positive ☐ Negative		
positive serology	Serologic Immunity (IgG antibody titer)	//	Quantitative Titer Results:	IU/ml		
Tetanus-diphtheria-pert	t ussis – One (1) dose of adult Tdap. If last Tdap is mo	ore than 10 years old, pr	ovide dates	of last Td and Tdap		
	Tdap Vaccine (Adacel, Boostrix, etc)					
	Td Vaccine (if more than 10 years since last Tdap)					
Varicella (Chicken Pox) - 2 doses of vaccine or positive serology						
	Varicella Vaccine #1		Serology Results			
	Varicella Vaccine #2		Qualitative Titer Results:	☐ Positive ☐ Negative		
	Serologic Immunity (IgG antibody titer)		Quantitative Titer Results:	IU/ml		
Influenza Vaccine - 1 dose annually each fall						
Date of last dose		Date				
2 2.12 57 7451 4500	Flu Vaccine					



lame: Date of Birth:					
(La	ast, First, Middle Initial)	(mm/dd/yyyy)			
QUANTITATIVE Hepatitis B Statest result is negative, repeat a	n - 3 doses of Engergix-B, Recombivax or Twinrix va urface Antibody test drawn 4-8 weeks after last vaccin nother Hepatitis B vaccine series followed by a repea a "non-responder" status is assigned. See: http://www	ne dose. A test titer <u>></u> 10i t test titer.If the Hepatitis	mIU/mL is positive for imm s B Surface Antibody test :	nunity. If the is negative	Copy Attached
	3-dose vaccines (Energix-B, Recombivax, Twinrix) 2-dose vaccines (Heplisav-B)	3 Dose Series	2 Dose Series		
Primary Hepatitis B Series	Hepatitis B Vaccine Dose #1				
Heplisav-B only requires two	Hepatitis B Vaccine Dose #2				
doses of vaccine followed by antibody testing	Hepatitis B Vaccine Dose #3				
	QUANTITATIVE Hep B Surface Antibody Test		mIU/mI		
Repeat		3 Dose Series	2 Dose Series		
Hepatitis B Series	Hepatitis B Vaccine Dose #4				
Only If no response to primary series	Hepatitis B Vaccine Dose #5				
Heplisav-B only requires two doses of vaccine followed by	Hepatitis B Vaccine Dose #6				
antibody testing	QUANTITATIVE Hep B Surface Antibody Test		mIU/mI		
Hepatitis B Vaccine Non-responder If the Hepatitis B Surface Antibody test is negative (titer less than 10 mIU/mL) after a primary and repeat vaccine series, vaccine non-responders should be counseled and evaluated appropriately. Certain institutions may request signing an "acknowledgement of non-responder status" document before clinical placements.			ed and		
	Additional Document	ation			
include meningitis vaccine	eve additional requirements depending upon rot which is mandated in some states if you live in a you may also be required to provide proof of v	dormitory style hous	ing. If you will be partic		
Vaccination, Test or Examination		Date	Result or Interp	retation	
Physical Exam (if required)		/			
		/			
		'			



Name:		Date of Birth:	
(La	ast, First, Middle Initial)		(mm/dd/yyyy)

TUBERCULOSIS (TB) SCREENING – All U.S. healthcare personnel are screened pre-placement for TB. Results of the last (2) TB Skin Tests (TSTs)) or (1) IGRA blood test are required <u>regardless</u> of prior BCG status. The 2-step TST protocol must have been placed within the past 12 months prior to clinical duties, and must have been performed in the U.S. The second TST must be placed at least 1 week after the first TST read date. If you have a history of a positive TST (PPD)≥10mm or a positive IGRA blood test, please supply information regarding any evaluation and/or treatment below. You only need to complete ONE section, A or B.

Skin test or IGRA results should not expire during proposed elective rotation dates

or

must be updated with the receiving institution prior to rotation.

Tuberculosis Screening History						
	Section A		Date Placed	Date Read	Result	Interpretation
		TST #1			mm □ Pos □ Neg □ Eq	
λ		TST #2		//	mm	☐ Pos ☐ Neg ☐ Equiv
se complete only one TB section based on your history	History of Negative TB Skin Test or Blood					
, h	Test					
mc				Date	Result	
n yc	T-spots or QuantiFERON TB Gold blood tests for	QuantiFERON TB (Interferon Gamma Relea		//	☐ Positive ☐ Neg	ative 🗖 Indeterminate
o p	tuberculosis Use additional rows as needed	QuantiFERON TB (Interferon Gamma Relea		/	☐ Positive ☐ Neg	ative 🗖 Indeterminate
ase						
on b						
tic	Section B		Date Placed	Date Read	Result	
sec		Positive TST	/	/	mm	
ΓB				Date	Result	
ne .	History of	QuantiFERON TB (Interferon Gamma Relea	Gold or T-Spot sing Assay)	//	□ Positive □ Ne	egative 🚨 Indeterminate
ly o	Positive Skin Test or	Chest X-ray*			*Provide documer	ntation or result
on	Positive Blood Test	Treated for latent TB infection (LTBI)?			☐ Yes ☐ No	
lete						
dmo						
၁၁		Date of Last Annual TB Symptom Questionnaire				
Se						
Plea						
4						



ne:		Date of Birth:
	(Last, First, Middle Initial)	Date of Birth: (mm/dd/yyyy)
	Addition	al Information
	MUST BE SIGNED BY A LICENSED	HEALTHCARE PROFESSIONAL OR DESIGNEE:

Healthcare Professional Signature:		Date:/
Printed Name:		Office Use Only
Title:		Office Ose Offiy
Address Line 1:		
Address Line 2:		
City:		
State:		
Zip:		
Phone:	() Ext:	
Fax:	()	
Email Contact:		

*Sources:

- 1. Hepatitis B In: Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. Hamborsky J, Kroger A, Wolfe S, eds. 13th ed. Washington D.C. Public Health Foundation, 2015
- 2. Immunization of Health-Care Personnel: Recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR, Vol 60(7):1-45
- 3. CDC Guidance for Evaluating Health-Care Personnel for Hepatitis B Virus Protection and for Administering Postexposure Management, MMWR, Vol 62(RR10):1-19
- 4. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, MMWR Vol 67(1):1-31
- 5. Sosa LE, Nijie GL, Lobato MN, et.al. Tuberculosis Screening, Testing, and Treatment of U.S. Health Care Personnel: Recommendations from National Tuberculosis Controllers Association and CDC, 2019. MMWR2019;68:439-443. https://www.cdc.gov/mmwr/volumes/68/wr/mm6819a3.htm?s cid+mm6819a3 w